Finding molecular signs linked to living past 100 using AI

Identifying molecular traits associated with extreme human longevity using an AI based integrative approach

NIH-funded research University of California, San Francisco · NIH-11333139

Using AI to spot genetic and blood markers tied to living past 100, to help guide healthier aging for older adults.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionUniversity of California, San Francisco NIH-funded
Lab location1 site (San Francisco, United States)
Project IDNIH-11333139 on NIH RePORTER

What this research studies

The team will combine health, genetic, and other molecular data from long-term studies (including the Framingham Heart Study and the Longevity Consortium) and lab datasets to find patterns tied to extreme longevity. Experts in clinical aging, genetic epidemiology, biology of aging, and AI will build integrative models that merge multiple 'omics' types (genes, proteins, metabolites) across studies. They will test and refine AI methods to identify biomarkers that track healthy aging and predict long-term outcomes. The goal is to speed up discovery of measurable markers that could point to treatments or tests for healthier aging.

Who could benefit from this research

Good fit: Ideal candidates are older adults—especially people aged 100+ or participants in long-term aging cohorts—who can contribute health records or biospecimens to aging studies.

Not a fit: People without long-term clinical records, biospecimens, or aging-related data (for example, younger healthy volunteers with no follow-up) are unlikely to directly benefit from this grant's work.

Why it matters

Potential benefit: If successful, this could identify measurable biomarkers that help predict and target healthy aging, potentially speeding development of therapies to reduce age-related disease.

How similar studies have performed: Previous work (such as epigenetic clocks and other biomarker studies) has shown promise, but applying integrative AI across many omics specifically for extreme longevity is relatively new.

Where this research is happening

San Francisco, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.